Vie Ventures at FASI-10 Summit
Challenges and Opportunities in Food Allergy Drug Development
Steven St. Peter, M.D., Founder and Managing Director of Vie Ventures, joined the Food Allergy Science Initiative's FASI-10 Summit on October 7th, 2026, for a panel on the challenges and opportunities in food allergy drug development, moderated by FASI's CEO, Carlos Bosques, Ph.D.
During the discussion, Steven highlighted why looking across disease areas matters: therapies developed for another disease could ultimately have meaningful applications in food allergy.
For families focused on food allergy, supporting progress can include looking beyond that disease for promising approaches. This perspective reflects Vie's interest in connecting disease-focused expertise and philanthropy with therapeutic development across diseases.
Watch the segment above for Steven's perspective on allergen-specific and allergen-agnostic therapies, and why potential advances may come from beyond food allergy.
